Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Type 1 diabetes mellitus (T1DM) increases the risk of atherosclerotic cardiovascular disease (CVD) in humans by poorly understood mechanisms. Using mouse models of T1DM-accelerated atherosclerosis, we found that relative insulin deficiency rather than hyperglycemia elevated levels of apolipoprotein C3 (APOC3), an apolipoprotein that prevents clearance of triglyceride-rich lipoproteins (TRLs) and their remnants. We then showed that serum APOC3 levels predict incident CVD events in subjects with T1DM in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. To explore underlying mechanisms, we investigated the impact of Apoc3 antisense oligonucleotides (ASOs) on lipoprotein metabolism and atherosclerosis in a mouse model of T1DM. Apoc3 ASO treatment abolished the increased hepatic Apoc3 expression in diabetic mice - resulting in lower levels of TRLs - without improving glycemic control. APOC3 suppression also prevented arterial accumulation of APOC3-containing lipoprotein particles, macrophage foam cell formation, and the accelerated atherosclerosis in diabetic mice. Our observations demonstrate that relative insulin deficiency increases APOC3 and that this results in elevated levels of TRLs and accelerated atherosclerosis in a mouse model of T1DM. Because serum levels of APOC3 predicted incident CVD events in the CACTI study, inhibiting APOC3 might reduce CVD risk in T1DM patients.

[1]  M. Budoff,et al.  Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D , 2019, Journal of Lipid Research.

[2]  Christian M. Metallo,et al.  ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance[S] , 2019, Journal of Lipid Research.

[3]  C. Ware,et al.  PIXUL-ChIP: integrated high-throughput sample preparation and analytical platform for epigenetic studies , 2019, Nucleic acids research.

[4]  C. Kahn,et al.  Multi-dimensional Transcriptional Remodeling by Physiological Insulin In Vivo. , 2019, Cell reports.

[5]  R. Horenstein,et al.  Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Merlin C. Thomas,et al.  Metabolic Karma—The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture , 2018, Diabetes.

[7]  Samuel X. Lee,et al.  FoxO transcription factors are required for hepatic HDL cholesterol clearance , 2018, The Journal of clinical investigation.

[8]  D. Nathan,et al.  The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study , 2017, Diabetologia.

[9]  V. Chair,et al.  Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Ildikó V. Tóth,et al.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels , 2017, Nature Medicine.

[11]  S. Young,et al.  Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL[S] , 2017, Journal of Lipid Research.

[12]  M. Febbraio,et al.  Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes , 2017, The Journal of clinical investigation.

[13]  K. Bornfeldt,et al.  Inflammatory stimuli induce acyl-CoA thioesterase 7 and remodeling of phospholipids containing unsaturated long (≥C20)-acyl chains in macrophages[S] , 2017, Journal of Lipid Research.

[14]  Björn Eliasson,et al.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.

[15]  Daniel G. MacArthur,et al.  Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity , 2017, Nature.

[16]  Xiaoke Yin,et al.  Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III , 2017, Journal of the American College of Cardiology.

[17]  J. Borén,et al.  Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease? , 2016, Current Atherosclerosis Reports.

[18]  Richard G. Lee,et al.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. , 2016, The Journal of clinical investigation.

[19]  K. Bornfeldt.  Does Elevated Glucose Promote Atherosclerosis? Pros and Cons. , 2016, Circulation research.

[20]  Richard G. Lee,et al.  Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes , 2016, Diabetes Care.

[21]  M. Brownlee,et al.  Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes. , 2016, Circulation research.

[22]  Mei Han,et al.  Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. , 2015, Cardiovascular research.

[23]  D. Gaudet,et al.  Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. , 2015, The New England journal of medicine.

[24]  I. D. de Boer,et al.  A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects. , 2015, Journal of proteome research.

[25]  M. Graham,et al.  Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia , 2015 .

[26]  F. Sacks.  The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia , 2015, Current opinion in lipidology.

[27]  G. Jarvik,et al.  Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. , 2015, Journal of proteomics.

[28]  B. Zinman,et al.  Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.

[29]  D. Gaudet,et al.  Targeting APOC3 in the familial chylomicronemia syndrome. , 2014, The New England journal of medicine.

[30]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[31]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[32]  M. Laakso,et al.  Insulin resistance and hyperglycaemia in cardiovascular disease development , 2014, Nature Reviews Endocrinology.

[33]  D. Nathan,et al.  Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study , 2013, Diabetes.

[34]  D. Nathan,et al.  Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study , 2013, Diabetes Care.

[35]  Richard G. Lee,et al.  Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.

[36]  A. Tall,et al.  Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. , 2013, Cell metabolism.

[37]  O. Soehnlein,et al.  Hypercholesterolemia links hematopoiesis with atherosclerosis , 2013, Trends in Endocrinology & Metabolism.

[38]  A. Tall,et al.  Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis. , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[39]  R. Coleman,et al.  Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1 , 2012, Proceedings of the National Academy of Sciences.

[40]  M. Taskinen,et al.  Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[41]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[42]  Brendan MacLean,et al.  Skyline: an open source document editor for creating and analyzing targeted proteomics experiments , 2010, Bioinform..

[43]  J. Borén,et al.  ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan , 2009, Diabetes.

[44]  P. Talmud,et al.  Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. , 2009, Atherosclerosis.

[45]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[46]  A. Chait,et al.  Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice , 2008, Proceedings of the National Academy of Sciences.

[47]  S. Schwartz,et al.  Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice. , 2006, The American journal of pathology.

[48]  J. Xu,et al.  Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. , 2004, The Journal of clinical investigation.

[49]  A. Chait,et al.  Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. , 2004, The Journal of clinical investigation.

[50]  J. Hokanson,et al.  Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. , 2003, Diabetes.

[51]  R. Krauss,et al.  ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan Published, JLR Papers in Press, September 1, 2002. DOI 10.1194/jlr.M200322-JLR200 , 2002, Journal of Lipid Research.

[52]  J. Breslow,et al.  Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. , 1995, The Journal of clinical investigation.

[53]  K. Williams,et al.  The response-to-retention hypothesis of early atherogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[54]  J. Breslow,et al.  Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. , 1994, Journal of lipid research.

[55]  Henry N. Ginsberg,et al.  Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. , 1992, The Journal of clinical investigation.

[56]  H. Ginsberg.  Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis , 1991, Diabetes Care.

[57]  R. Mahley,et al.  Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. , 1990, The Journal of biological chemistry.

[58]  R. Havel,et al.  Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. , 1985, Journal of lipid research.

[59]  M. Muller,et al.  Acute phase reactants of mice. I. Isolation of serum amyloid P-component (SAP) and its induction by a monokine. , 1982, Journal of immunology.

[60]  P. Nestel,et al.  Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. , 1981, Journal of lipid research.